Xequel Bioincis A Clinical Stage Biopharmaceutical Company Advancing Its Proprietary Act1Alpha Connexin Carboxyl Terminal 1 Peptidetechnology Platform To Develop Drugs That Will Enable Physicians To Better Manage A Variety Of Indications Involving Inflammation And The Body S Response To Injury Act1 Is A Patented New Chemical Entity Currently In Development For Multiple Indicationsthe Company S Lead Clinical Programs Include Granexinagel In Dermatology And Inexintm Ophthalmic Solution In Ophthalmologythe Company Also Has Ongoing Preclinical Research In Pulmonology
No conferences found for this company.
| Company Name | Firststring Research Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
